Suzan Y. Alharbi
Suzan Y. Alharbi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Seraj Makkawi
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
2 shared publications Abdulaziz A Alqarni
King Saud bin Abdulaziz Univ Hlth Sci, Coll Med, Jeddah, Saudi Arabia
1 shared publication- Ahmad Rida Abuzinadah
Department of Neurology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia
1 shared publication - Amal M. Alosaimi
Oncology, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Jeddah, SAU
1 shared publication - Amirah S. Algethami
Department of Oncology, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, SAU
1 shared publication Anmar Fatani
Department of Neurology, Ministry of The National Guard Health Affairs, Jeddah 22384, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 14 January 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (2)
The Role of the Discharge Planning Team on the Length of Hospital Stay and Readmission in Patients with Neurological Conditions: A Single-Center Retrospective Study
Background: Emerging evidence highlights the critical role of discharge planning teams in enhancing patient care. However, there is lack of data regarding how the implementation of a discharge planning system influences the length of stay (LOS) in hospital and readmission rates among patients with neurological diseases. We conducted a retrospective analysis to examine the effects of discharge planning application on the LOS and readmission rates for patients admitted under the neurology service in Saudi Arabia. Methods: This is a retrospective study conducted at King Abdulaziz Medical City—Western region of Saudi Arabia. We included all patients admitted and discharged under the neurology service between January 2018 and December 2019. The included patients who were divided into the 2018 group (not exposed to discharge planner) and the 2019 group (exposed to discharge planner). The primary endpoints were the LOS and readmission rates. Results: The study included 856 patients (436 allocated to the 2019 group and 420 allocated to the 2018 group). There was no difference between the two groups in the LOS after adjusting confounding factors (β = −0.58, 95% CI [−2.79, 1.61], p = 0.60). However, the 2019 group were more likely to be discharged within three days compared to the 2018 group (41% vs. 26%, p < 0.005). Our analysis showed that patients in the 2019 group were less likely to be readmitted compared to the 2018 group (adjusted odds ratio = 0.70, 95% CI [0.49–0.99], p = 0.0442). Conclusions: Implementation of a discharge planning team was associated with higher early discharge rates and lower hospital readmissions, suggesting potential benefits for healthcare resource utilization in neurological services.
- 14 January 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (2)
Open AccessThe Role of the Discharge Planning Team on the Length of Hospital Stay and Readmission in Patients with Neurological Conditions: A Single-Center Retrospective Study
Background: Emerging evidence highlights the critical role of discharge planning teams in enhancing patient care. However, there is lack of data regarding how the implementation of a discharge planning system influences the length of stay (LOS) in hospital and readmission rates among patients with neurological diseases. We conducted a retrospective analysis to examine the effects of discharge planning application on the LOS and readmission rates for patients admitted under the neurology service in Saudi Arabia. Methods: This is a retrospective study conducted at King Abdulaziz Medical City—Western region of Saudi Arabia. We included all patients admitted and discharged under the neurology service between January 2018 and December 2019. The included patients who were divided into the 2018 group (not exposed to discharge planner) and the 2019 group (exposed to discharge planner). The primary endpoints were the LOS and readmission rates. Results: The study included 856 patients (436 allocated to the 2019 group and 420 allocated to the 2018 group). There was no difference between the two groups in the LOS after adjusting confounding factors (β = −0.58, 95% CI [−2.79, 1.61], p = 0.60). However, the 2019 group were more likely to be discharged within three days compared to the 2018 group (41% vs. 26%, p < 0.005). Our analysis showed that patients in the 2019 group were less likely to be readmitted compared to the 2018 group (adjusted odds ratio = 0.70, 95% CI [0.49–0.99], p = 0.0442). Conclusions: Implementation of a discharge planning team was associated with higher early discharge rates and lower hospital readmissions, suggesting potential benefits for healthcare resource utilization in neurological services.
- Open Access
- 6 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e20989
Atypical Familial Amyotrophic Lateral Sclerosis Secondary to Superoxide Dismutase 1 Gene Mutation With Coexistent Axonal Polyneuropathy: A Challenging Diagnosis
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that involves both the upper and lower motor neurons. Familial ALS, including superoxide dismutase 1 (SOD1) mutation, accounts for 5-10% of all cases of ALS. Typically, the symptoms of ALS are purely motor, though coexistent sensory symptoms have been reported in rare cases. In this report, we describe the case of a 47-year-old man who presented with progressive bilateral lower limb weakness and numbness for the last four years. A nerve conduction study (NCS) showed evidence of coexistent axonal sensorimotor polyneuropathy in addition to the typical findings of ALS in needle electromyography. Genetic testing confirmed the diagnosis of familial ALS secondary to the SOD1 genetic mutation. This report highlights that the presence of sensory symptoms should not exclude the possibility of ALS in an appropriate clinical setting.
- 6 January 2022
- Published by Springer Nature in Cureus
- Vol. 14 (1) , e20989
Open AccessAtypical Familial Amyotrophic Lateral Sclerosis Secondary to Superoxide Dismutase 1 Gene Mutation With Coexistent Axonal Polyneuropathy: A Challenging Diagnosis
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that involves both the upper and lower motor neurons. Familial ALS, including superoxide dismutase 1 (SOD1) mutation, accounts for 5-10% of all cases of ALS. Typically, the symptoms of ALS are purely motor, though coexistent sensory symptoms have been reported in rare cases. In this report, we describe the case of a 47-year-old man who presented with progressive bilateral lower limb weakness and numbness for the last four years. A nerve conduction study (NCS) showed evidence of coexistent axonal sensorimotor polyneuropathy in addition to the typical findings of ALS in needle electromyography. Genetic testing confirmed the diagnosis of familial ALS secondary to the SOD1 genetic mutation. This report highlights that the presence of sensory symptoms should not exclude the possibility of ALS in an appropriate clinical setting.
- Open Access
- 11 December 2020
- Published by Springer Nature in Cureus
- Vol. 12 (12)
Aggressive Angiomyxoma of the Posterior Wall of the Uterus
Aggressive angiomyxoma (AA) is a rare benign mesenchymal tumor that usually arises in the vulvovaginal and perineal regions of premenopausal females. The treatment of choice is surgical excision. Hormonal therapy or radiotherapy have emerged as alternative forms of treatment but are indefinite. In this article, we report a case of aggressive angiomyxoma in the posterior wall of the uterus of a 35-year-old Saudi female patient. The clinical data, imaging, histopathology, treatment, and prognosis were analyzed, and related literatures were reviewed. The frequency of recurrence in these tumors emphasizes the importance of long-term follow-ups.
- 11 December 2020
- Published by Springer Nature in Cureus
- Vol. 12 (12)
Open AccessAggressive Angiomyxoma of the Posterior Wall of the Uterus
Aggressive angiomyxoma (AA) is a rare benign mesenchymal tumor that usually arises in the vulvovaginal and perineal regions of premenopausal females. The treatment of choice is surgical excision. Hormonal therapy or radiotherapy have emerged as alternative forms of treatment but are indefinite. In this article, we report a case of aggressive angiomyxoma in the posterior wall of the uterus of a 35-year-old Saudi female patient. The clinical data, imaging, histopathology, treatment, and prognosis were analyzed, and related literatures were reviewed. The frequency of recurrence in these tumors emphasizes the importance of long-term follow-ups.